A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92)

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• M. M. Sgroi, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, Z. Hammoud, M. Yu, H. Choy, C. Beccera. Pre-Operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
• A.K. Agarwala, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, M. Yu, Y. Tong, C.R. Beccera, H.Choy. Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group (HOG) and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL J Clin Oncol 27:15s, 2009 (suppl; abstr 4557)

Manuscripts/Articles:

• Becerra CR, Hanna N, McCollum AD, Bechar N, Timmerman RD, Dimaio M, Kesler KA, Yu M, Yan T, Choy H. A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group GI05-92. J Thorac Oncol. 2013 Sep 30. [Epub ahead of print] PMID: 24084441
• Beccera C, Hanna N, McCollum A, Bechar N, Timmerman R, DiMaio M, Kesler K, Yu M, Yan T, Choy H. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GEJ junction carcinomas: Hoosier Oncology Group GI05-92. J Thorac Oncol 2013 Nov;8(11):1425-9. doi: 10.1097/JTO.0b013e3182a46c3b